Document:

EX-10.1

 Exhibit 10.1 

SEPARATION AND RELEASE AGREEMENT 

THIS Separation and Release Agreement (this “Agreement”), by and between Stephen S. Unger
(“Executive”) and Quotient Limited (the “Company”), is dated as of November 2, 2016. 

WHEREAS, the Executive and the Company entered into an Employment Agreement, dated March 5, 2014 (the “Employment
Agreement”); 
 WHEREAS, the Executive and the Company have agreed that Executive’s employment with the Company and its
affiliates terminated on November 2, 2016 (the “Termination Date”); and 
 WHEREAS this Agreement serves to set
forth the terms and conditions of the Executive’s termination of employment from the Company and its affiliates. 
 NOW, THEREFORE, the
Executive and the Company agree as follows: 
  

	 	1.	Termination from the Company. The Executive’s employment with the Company and its affiliates terminated on the Termination Date. As of the Termination Date, Executive will resign all positions he holds as an
officer, director and employee of the Company and its affiliates, and will promptly execute such documents and take such actions as may be necessary or reasonably requested by the Company to effectuate or memorialize the resignation from such
positions. 

  

	 	2.	Certain Obligations, Payments and Benefits. 

  

	 	(a)	Subject to Executive’s compliance with Sections 6, 12 and 13 of the Employment Agreement and Section 8 of this Agreement, the Company shall pay to the Executive an amount equal to $325,000, in a lump sum on
the first regularly scheduled payroll date following his execution of this Agreement (the “Payment Date”), and provide the Executive continued participation in the Company’s medical and life insurance plans on the same
basis on which Executive or any of his eligible dependents participated as of the Termination Date. Such twelve months of continued participation shall count towards the Executive’s 18-month COBRA continuation coverage. 

 

	 	(b)	Executive and the Company further agree, subject to Executive’s compliance with Sections 6, 12 and 13 of the Employment Agreement and Section 8 of this Agreement: 

 

	 	(i)	Executive holds an option to purchase 32,000 ordinary shares of the Company, dated June 28, 2013. Such option shall remain exercisable until November 2, 2017, after which it will be forfeited to the extent not
previously exercised. 

  

	 	(ii)	Executive holds an option to purchase 67,200 ordinary shares of the Company, dated March 4, 2014 (the “March 2014 Option”), 22,400 of which remain unvested as of the Termination Date. Such
22,400 unvested options shall vest on March 4, 2017. The March 2014 Option, to the extent vested, shall remain exercisable until November 2, 2017, after which it will be forfeited to the extent not previously exercised. 

	 	(iii)	Executive holds an option to purchase 50,800 ordinary shares of the Company, dated April 29, 2014 (the “April 2014 Option”), 16,933 of which remain unvested as of the Termination Date. Such
16,933 unvested options shall vest on April 29, 2017. The April 2014 Option, to the extent vested, shall remain exercisable until November 2, 2017, after which it will be forfeited to the extent not previously exercised. 

 

	 	(iv)	Executive holds an option to purchase 22,500 ordinary shares of the Company, dated May 20, 2015, 15,000 of which remain unvested as of the Termination Date (the “May 2015 Option”). The May
2015 Option shall vest with respect to an additional 7,500 ordinary shares on May 20, 2017. The balance of the May 2015 Option (covering 7,500 ordinary shares) shall be forfeited on the Termination Date. The May 2015 Option, to the extent
vested, shall remain exercisable until November 2, 2017, after which it will be forfeited to the extent not previously exercised. 

  

	 	(v)	Executive holds an option to purchase 15,000 ordinary shares of the Company, dated June 1, 2016, (the “June 2016 Option”), all of which remain unvested as of the Termination Date. The June
2016 Option shall vest with respect to an additional 5,000 ordinary shares on June 1, 2017. The balance of the June 2016 Option (covering 10,000 ordinary shares) shall be forfeited on the Termination Date. The June 2016 Option, to the extent
vested, shall remain exercisable until November 2, 2017, after which it will be forfeited to the extent not previously exercised. 

  

	 	(vi)	Executive holds an award of 22,500 multi-year restricted share units, dated May 20, 2015, all of which shall be forfeited on the Termination Date. 

 

	 	(vii)	Executive holds an award of 15,000 multi-year restricted share units, dated June 1, 2016 (the “June 2016 MRSUs”), all of which shall be forfeited on the Termination Date. 

 

	 	(c)	For the avoidance of doubt, the Executive’s rights to the payments and benefits under Sections 2(a) and 2(b) hereof shall be forfeited if he breaches Section 6, 12 or 13 of the Employment Agreement or
Section 8 of this Agreement. 

  
 - 2 - 

	 	(d)	Executive shall be entitled to payments and benefits which as of the Termination Date are vested under the Company’s group health benefit and retirement plans, if any. 

 

	 	(e)	On the first payroll date following the Termination Date, the Company shall pay the Executive an amount in full satisfaction of his accrued and unused vacation and paid time-off time, such amount to be agreed between
the Company and the Executive. 

  

	 	(f)	Upon presentation to the Company within 30 days of the Termination Date of documentation reasonably acceptable to the Company, the Company shall reimburse Executive for unpaid business expenses incurred by him prior to
the Termination Date in accordance with Company policy. 

  

	 	3.	Executive Acknowledgement. Executive acknowledges that the amounts set forth in Section 2 comprise the sole consideration the Executive is entitled to in connection with his employment and the termination
thereof. 

  

	 	4.	Release of Claims. 

  

	 	(a)	In consideration for the payments and benefits set forth in Section 2 hereof, Executive (on his own behalf and on behalf of his heirs, executors, and administrators) agrees to and hereby does unconditionally waive,
release and forever discharge the Company and any and all of its past, present or future parents, subsidiaries, affiliates, and related persons or entities, including, but not limited, to all of its or their officers, directors, managers, employees,
shareholders, members, partners, agents, attorneys, and successors and assigns (the “Released Parties”), from any and all actions, claims, demands and damages, whether actual or potential, known or unknown, which he has, may
have or claim to have, against the Released Parties as of the date he signs this Agreement, including, without limitation, any and all claims related or in any manner incidental to (i) Executive’s employment with the Company through and
including the Termination Date and (ii) any events that have transpired prior to and including the date of the Agreement. All such claims are forever barred by this Agreement regardless of the forum in which such claims might be brought,
including, but not limited to, claims (x) under any federal, state or local law governing the employment relationship through the Termination Date (including, but not limited to, Title VII of the Civil Rights Acts of 1964 and 1991, the
Americans with Disabilities Act, the Family Medical Leave Act, the Employee Retirement Income Security Act of 1974, the Rehabilitation Act, the Worker Adjustment and Retraining Notification Act, the New York State Human Rights Law and Sexual
Orientation Non-Discrimination Act, the New York City Human Rights Law and any state, local, and other federal employment laws, and any amendments to any of the foregoing or (y) under the common law for breach of contract, wrongful discharge,
personal injuries and/or torts. The Executive understands that this is a general waiver and release of all claims, known or unknown, that he may have against the Released Parties based on any act, omission, matter, cause or thing that occurred
through the date of his execution of this Agreement. 

  
 - 3 - 

	 	(b)	The above release does not waive claims (i) that may arise after the date the Executive signs this Agreement, (ii) which cannot be released by private agreement or (iii) under this Agreement. In addition,
this Agreement does not extend to, release or modify any rights to indemnification or advancement of expenses to which the Executive is entitled from the Company or its insurers under the Company’s certificate of incorporation, bylaws, or other
corporate governing documents or applicable law. 

  

	 	(c)	Additionally, the parties agree that this Agreement shall not preclude the Executive from filing any charge with the Equal Employment Opportunity Commission, the National Labor Relations Board, or any other governmental
agency or from in any way participating in any investigation, hearing, or proceeding of any government agency (though the Executive affirmatively waives any right to receive individual relief in connection with his participation in such claims).

  

	 	(d)	Executive acknowledges and agrees that he is providing the waiver and release set forth herein in exchange for consideration in addition to anything of value to which Executive may already have been entitled.

  

	 	5.	Affirmations. Executive affirms that he has not filed or caused to be filed, and is not a party to, any claim, complaint, or action against the Company or any of its affiliates in any forum or form. Executive
also affirms that he has no known workplace injuries or occupational diseases, and has been provided and has not been denied any leave requested under the Family and Medical Leave Act. 

 

	 	6.	Restrictive Covenants. Executive acknowledges and agrees that any and all of the covenants set forth in Sections 6, 12 and 13 of the Employment Agreement will continue in full force and effect in accordance
with the terms and conditions thereof notwithstanding the termination of his employment. 

  

	 	7.	Company Property. Executive agrees to return to the Company all work product, electronic devices and other property of the Company, including, but not limited to, equipment, supplies, keys, security items, credit
cards, passwords and electronic devices, within 7 days following the Termination Date. 

  

	 	8.	Non-Disparagement. Executive agrees that he will not at any time defame, disparage or make statements or disparaging remarks which could embarrass or cause harm to the Company, its affiliates, or its or their
officers, directors, managers, employees or shareholders. This Section 8 does not apply to statements made pursuant to court proceedings or under penalty of perjury; provided, however, that the Executive agrees to give the Company advance
notice of such an event, to the extent practicable. Executive shall refer all inquiries from the Company’s employees and investors regarding his termination to Paul Cowan. 

  
 - 4 - 

	 	9.	Consultation with Attorney; Voluntary Agreement. Executive acknowledges that (a) the Company has advised him of his right to consult with an attorney of his own choosing prior to executing this Agreement,
(b) Executive has carefully read and fully understands all of the provisions of this Agreement, and (c) Executive is entering into this Agreement knowingly, freely and voluntarily in exchange for good and valuable consideration.

  

	 	10.	Governing Law. This Agreement will be governed by and construed and enforced according to the laws of the State of Delaware, without regard to conflicts of laws principles thereof. 

 

	 	11.	Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city, foreign or other taxes as the Company is required to withhold pursuant to any applicable law, regulation or
ruling. Notwithstanding any other provision of this Agreement, the Company shall not be obligated to guarantee any particular tax result for Executive with respect to any payment provided hereunder, and Executive shall be responsible for any taxes
imposed on him with respect to any such payment. 

  

	 	12.	Entire Agreement. This Agreement constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes, terminates, and replaces any prior or contemporaneous
understandings or agreements with respect thereto, except for Sections 6, 12 and 13 of the Employment Agreement, which shall remain in full force and effect in accordance with its terms. 

 

	 	13.	Sections 409A and 457A. This Agreement and the payments to be made hereunder are intended to comply with, or be exempt from, Sections 409A and 457A of the Internal Revenue Code of 1986 and the regulations and
guidance issued thereunder, each as amended, and this Agreement will be interpreted, and all tax filings with the Internal Revenue Service will be made, in a manner consistent with that intent. 

 

	 	14.	Modifications. This Agreement may not be changed, amended, or modified unless done so in a writing signed by the Company and Executive. 

 

	 	15.	Counterparts. This Agreement may be executed in separate counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument. 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 - 5 - 

 IN WITNESS WHEREOF, Executive and the Company have executed this Agreement as of the date first
written above. 
  

	
	STEPHEN S. UNGER
	
	/s/ Stephen Unger
	Date: November 9, 2016

  

	
	QUOTIENT LIMITED
	
	By: /s/ Paul Cowan
	Name: Paul Cowan
	Title: Chief Executive Officer
	Date: November 2, 2016

  
 - 6 -Exhibit
10.2

 

12/10/2015

COLLABORATIVE AGREEMENT

 

Made
and entered into as of this 29th day of December 2015 ("the Effective Date")

 

BY
AND BETWEEN

 

BioLite
Inc., a company incorporated under the laws of Taiwan and having its principal place of business at 3rd Floor, 248, Nei-Hu
Road, Sec. 1, Taipei, 11493 Taiwan (“BioLite”)

 

AND

 

American
BriVision Corporation, a company incorporated under the laws of USA and having it principle place of business at
11, Sawyer Park Drive, Goshen, New York 10294 USA (“ABVC”)

 

WITNESSETH:

 

WHEREAS, BioLite
has been granted licensing rights and/or established its own technology to develop and use proprietary technology and confidential
information for the following products (“Product”):

1.

BLI-1005
 CNS-Major Depressive Disorder

2.

BLI-1008  CNS-Attention
Deficit Hyperactivity Disorder

3.

BLI-1401-1 Anti-Tumor
Combination Therapy-Solid Tumor with Anti-PD-1

4.

BLI-1401-2 Anti-Tumor
Combination Therapy-Triple Negative Breast Cancer

5.

BLI-1501  Hematology-Chronic
Lymphocytic Leukemia

 

And their
related intellectual property rights, and has developed them for medicinal use in collaboration with outside researchers.

 

WHEREAS, ABVC
is a biotech company, and is in the business of research, development and marketing of, among others, new drugs and innovative
medical devices;

 

WHEREAS, ABVC
is willing to collaboratively develop and commercialize Product in certain Territory (as defined hereafter);

 

     

     

    

 

WHEREAS, the
Parties agree to jointly cooperate and commercialize Product in such Territory and enter into the Collaborative Agreement. The
parties agree this jointly Collaborative Agreement will be led by ABVC. Herein, it is agreed as follows:

 

1. Definitions
and Interpretation

 

1.1
"Confidential Information" shall mean all confidential, proprietary, trade secret, or non-public information, data and
experience, whether of scientific, technical, engineering, operational or economic nature, disclosed by one of the Parties (the
"Disclosing Party") to the other Party (the "Recipient") for the purpose of this Collaborative Agreement.

 

1.2
"Confidential Materials" shall mean any document, diskette, tape, writing or other tangible item to the extent that
such item contains or embodies any Confidential Information, whether in printed, handwritten, electronic, coded, magnetic or other
form and whether delivered by a Disclosing Party or made by a Recipient.

 

1.3
"Data" shall mean any and all research data, technical data, test and development data, CMC (chemistry, manufacturing
and control), pre-clinical and clinical data, formulations, processes, ideas, protocols, regulatory files and the like which are
developed by either Party under the Development Program in connection with its performance of this Collaborative Agreement.

 

1.4 “Field” shall
mean drug and therapeutic use of the Product based upon the Health Registration Approval and in no event include the use of the
Product for functional food, health food nor health supplement.

 

1.5
"Intellectual Property" shall mean any patent, copyright, mask work, trade secret, trademark or other proprietary right;
including, without limitation, all domestic and foreign applications and registrations therefore, and all renewals and extensions
relating thereto; with respect to patent application and patents, all domestic and foreign divisional, continuations, continuations-in-part,
substitutions, reissues, re-examinations, renewals and extensions relating thereto; all goodwill associated therewith, and all
benefits, privileges, causes of action and remedies relating to any of the foregoing proprietary rights (including, without limitation,
the right to use for all past, current or future infringements or violations of the foregoing proprietary rights, and the right
to settle and retain proceeds from any such actions).

 

1.6
"Territory" shall mean North America (USA and Canada).  

 

     

     

    

 

 

2. Agreement Grants
to ABVC.

BioLite
hereby grants sole licensing rightsto ABVC, in the Field and in the Territory under the Intellectual Property, Confidential Information,
Data and Trademark, to develop Product.

 

3. Milestone
Payment

 

3.1
Total payment shall be One Hundred (100) Million USDollars (non-refundable, before tax), paid in cash
or stock ofABVC with equivalent value.

 

3.2 The
payment shall be paid according to the following milestones:

 

3.2.1
upfront payment shall upon the signing of thisCollaborative Agreement: 3.5% of total payment.

  

3.2.1.1
after receiving upfront payment from ABVC, BioLite has to deliver all data to ABVC in one week.

 

3.2.2
upon the first IND submission, ABVC shall pay, but no later than Dec. 15th, 2016:
6.5% of total payment.

 

3.2.2.1 after receiving second
payment from ABVC, BioLite has to deliver IND package to ABVC in one week.

 

3.2.3 at
the completion of first phase II clinical trial, ABVC shall pay, but no later than Sep.15th,
2017: 15% of total payment.

 

3.2.3.1
after receiving third payment from ABVC, BioLite has to deliver phase II clinical study report to ABVC in three months.

 

3.2.4 upon
the phase III IND submission, ABVC shall pay,but no later than Dec. 15th, 2018: 20% of total payment.

 

3.2.4.1
after receiving forth payment from ABVC, BioLite has to deliver IND package to ABVC in one week.

 

     

     

    

 

3.2.5 at
the completion of phase III, ABVC shall pay, but no later than Sep. 15th, 2019 : 25% of
total payment.

 

3.2.5.1
after receiving fifth payment from ABVC, BioLite has to deliver phase III clinical study report to ABVC
in three months

 

3.2.6 upon
the NDA submission, ABVC shall pay, but no later than Dec. 15th, ABVC shall pay, 2020: 30% of
total payment.

 

3.2.6.1
after receiving sixth payment from ABVC, BioLite has to deliver NDA package to ABVC in one week

 

4.
 Royalty Charge: 5% of the net sales.

 

5.  Confidentiality

 

The
Parties agree that during the term of this Collaborative Agreement and thereafter ten (10) years Confidential Information exchanged
during the course of this Collaborative Agreement and will be accorded confidential treatment and shall not be used for any other
purpose than the performance of this Collaborative Agreement and the exercise of the rights herein provided.

 

The
Recipient’s obligation hereunder shall not apply to:

  

(a)
Information which is now or hereafter becomes part of the public domain in other ways than by faults, acts or omissions of the
Recipient;

(b)
Information which the Recipient can show by sufficient evidence was in its own possession prior to the time of receipt from the
Disclosing Party or is independently developed by or for the Recipient without reliance upon or use of any of the Disclosing Party's
Confidential Information or Confidential Materials;

(c)
Information which is required to be disclosed by statute or governmental rule or regulation or by a court or administrative body.

 

Nothing
herein shall prevent BioLite or ABVC from disclosing any of such Confidential Information to the extent that (i) such Confidential
Information is disclosed in connection with the securing of the IND or NDA, (ii) such information is disclosed for the purpose
of obtaining a governmental approval for the manufacture and/or sale of or effectuating the development, marketing and promotion
of any Product and/or API or (iii) such information is disclosed to the Sub-licensee(s) of BioLite or ABVC for the use thereof
upon executing a separate confidentiality disclosure agreement.

 

     

     

    

 

6.
Duration and Termination

 

6.1
Duration

This
Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen (15) years as of the first commercial
sales of the Product in the Territory and automatically renew for 5 more years unless either Party gives the other Party six (6)
month written notice of termination prior to the expiration date of the term.

 

6.2
Termination for Cause

 

This
Collaborative Agreement can be terminated by either Party for any of the following causes by giving to the other Party (“Breaching
Party”) thirty (30) day written notice of its intention to terminate for such causes as follows:

(a)

If
Breaching Party materially breaches any provision of this Agreement and such breach is not cured within thirty (30) day following
the written notice by Non-breaching Party; or

(b)

If
a Party is the subject of a voluntary petition in bankruptcy or any voluntary proceeding relating to insolvency, receivership,
liquidation, or composition for the benefit of creditors, if such petition or proceeding is not dismissed within thirty (30) days
of filing, or becomes the subject of any involuntary petition in bankruptcy or any involuntary proceeding relating to insolvency,
receivership, liquidation, or composition for the benefit of creditors, if such petition or proceeding is not dismissed within
thirty (30) days of filling.

 

Termination
is not the sole or exclusive remedy under this Agreement and, whether or not termination is effected, all other rights and remedies
at law or equity will remain available.

 

     

     

    

  

7. Miscellaneous

 

7.1
Notice

All
notices, requests, demands and other communications to be given in accordance with this Agreement shall be given in writing and/or
by prepaid registered mail or receipt return requested to the other Party at the following addresses:

 

If
to BioLite:

 

BioLite.
Inc.

 

3rd Floor,
248, Nei-Hu Road, Sec. 1, Taipei, 11493 Taiwan

 

Attention:
Webster Kiang

 

Title:
President

 

If
to ABVC:

 

American
BriVision Corporation

 

11,
Sawyer Park Drive, Goshen, New York 10294 USA Attention: Kazunori Kameyama

 

Title:
Chief Business Officer

  

7.2 Applicable
Law

This
Agreement and any disputes arising out of or relating thereto, including, without limitation, its interpretation, construction,
performance, and enforcement shall be governed by and construed in accordance with the laws of Taiwan.

 

7.3 Dispute Dissolution

Both
Parties shall endeavor to settle amicably and promptly any disputes, controversies and differences which may arise between the
Parties out of or in relation to this Agreement or any breach thereof.  In case such an amicable settlement is not attained,
the matter shall be finally settled by arbitration according to the Rules of Conciliation and Arbitration of the International
Chamber of Commerce, which rules shall be deemed incorporated into this paragraph. The place of arbitration will be Taipei (Taiwan).

 

7.4
Addendum or amendment may be added upon mutual agreement of the parties.

 

IN
WITNESS WHEREOF the Parties hereto have caused this Collaborative Agreement to be executed, in duplicate, each Party
taking a copy, as of the Effective Date.

 

	BIOLITE, INC.	 	American BriVision Corporation
	By:	 	 	By:	 	 
	Frank
    Liu	 	Kira
    Huang  
	Supervisor	 	CFO
     
	Date:	 	Date:  

  

     

     

    

 

MILESTONE
PAYMENT AGREEMENT

 

This
Milestone Payment Agreement (the “Agreement”) dated May 6, 2016 (“Execution Date”) is made and entered
into by and among by and among BioLite Inc., a company incorporated in Taiwan (the “Lender” or “BioLite”) and
American BriVision Corporation, a Nevada Corporation (the “Company” and together with Lender, the “Parties”)),
with reference to the following:

 

WHEREAS, the
Parties entered into a collaborative agreement dated December 29, 2015 (the “Collaborative Agreement”). Pursuant to
the Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payment,
shall be paid by ABVC upon signing of that agreement.

 

WHEREAS, The
Parties agree that the Milestone Payment shall made partially in cash in the amount of two million six hundred dollars ($2,600,000)
and the remaining nine hundred dollars ($900,000) in newly issued common shares, at the price of $1.60 per share, for an aggregate
number of 562,500 shares (the “Shares”).

 

NOW,
THEREFORE, in consideration of the provisions for payment and the mutual terms, conditions hereinafter set forth, the
Parties hereto agree as follows:

 

1.
Initial Payment.

Pursuant
to the Agreement, ABVC agrees to pay BioLite two million six
hundred dollars ($2,600,000) in cash and nine hundred dollars ($900,000)
in newly issued Share, at the price of $1.60 per share, for an aggregate number of 562,500 shares. Upon execution of the Agreement,
the Company shall [ ] the cash to the Lender and instruct the transfer agent to issue the Shares to the Lender. Once in receipt,
the Lender shall acknowledge the payment of $3,500,000 pursuant to the milestone payment clause of the Collaborative Agreement.

 

2.
No Further Changes. This Milestone Agreement shall be regarded as a supplement to the Collaborative Agreement and, other
than as set forth herein, the terms of the Collaborative Agreement shall remain in full force and effect without change or amendment
thereto. 

 

3.
Rules Governing the Agreement

3.1
Law and Jurisdiction

The
Agreement shall be construed and enforced in accordance with the laws of Taiwan made in writing and signed by both parties.

 

     

     

    

 

3.2
Representation or Warranties

 

The
Parties to the Agreement hereby represents and warrants to the other party that it has had an opportunity to seek the advice of
its own independent legal counsel with respect to the provisions of the Agreement and that its decision to execute the Agreement
is not based on any reliance upon the advice of any other party or its legal counsel. Each party represents and warrants to the
other party that in executing this Agreement such party has completely read this Agreement and that such party understands the
terms of this Agreement and its significance. This Agreement shall be construed neutrally, without regard to the party responsible
for its preparation.

   

The
Parties to the Agreement hereby represents and warrants to the other party that (i) the execution, performance and delivery
of the Agreement has been authorized by all necessary action by such party; (ii) the representative executing the Agreement
on behalf of such party has been granted all necessary power and authority to act on behalf of such party with respect to the
execution, performance and delivery of the Agreement; and (iii) the representative executing the Agreement on behalf of such
party is of legal age and capacity to enter into agreements which are fully binding and enforceable against such party.

 

4.
Notices

 

This
Milestone Payment Agreement may be executed in any number of counterparts and may be delivered by facsimile transmission, all
of which taken together shall constitute a single instrument.

 

IN
WITNESS WHEREOF the Parties hereto have caused this Milestone Payment Agreement to be executed, in duplicate, each Party
taking a copy, as of the Effective Date.

 

	BIOLITE, INC.	 	American BriVision Corporation
	 	 	 	 	 	 
	By:	/s/ Frank
    Liu	 	By:	/s/ Kira
    Huang	 
	 	Frank Liu	 	 	Kira Huang	 
	 	Supervisor	 	 	CFO	 
	Date:	 	 	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]